The global market for tissue sealing agents and hemostasis products estimated to reach $8.4 billion by 2027, expa9ding at a CAGR of 6.3% over the forecast period, driven by increasing preference for minimally invasive procedures, aging population, and technological advancements.
Medical device development has evolved with the complexity of surgical procedures being performed and the increased use of anticoagulation and antiplatelet therapies, wherein hemostatic agents provides an essential protective mechanism depending on the delicate balance of procoagulant and anticoagulant processes.
Topical hemostatic agents and tissue adhesives are used as an adjunct or alternative to standard surgical techniques (e.g., electrocautery, sutures) to manage bleeding from surgical surfaces.
- The need for advanced hemostatic products increases with the complexity of surgical procedures and use of anticoagulation and antiplatelet treatments.
- While current hemostatic treatments are already very effective and safe, new agents to enhance convenience and further improve both short- and long-term efficacy of treatment are under development.
- For example, HEMOPATCH (sealing hemostat) is a novel, advanced hemostatic pad that is composed of a synthetic, protein-reactive monomer and a collagen backing.
- While current hemostatic treatments are already very effective and safe, new agents to enhance convenience and further improve both short- and long-term efficacy of treatment are under development.
- Several newer hemostatic agents with an extended half-life are at an advanced stage of clinical development.
- The strategies being evaluated for hemostatic enhancement range from gene and nucleic acid-based approaches, to the development of complex, naturally occurring molecules such as the non-anticoagulant polysaccharide, fucoidan.
- There is every likelihood that combinations of these treatment approaches will further improve the quality of bleeding disease management over the next five years and beyond.
The global tissue sealing agents and hemostasis market report provides market size ($million 2019 to 2029), market share, growth trends and forecast (CAGR%, 2022 to 2029).
The global market for tissue sealing and hemostasis products segmented by product [adhesive and tissue sealing agents (adhesion barrier products, natural tissue sealants – fibrin sealants, other natural sealants such as albumin and collagen based); synthetic tissue sealants (cynoacrylate-based tissue adhesives, other synthetic tissue sealant such as PEG based); and topical hemostats (thrombin-based active hemostats, combination flowable hemostats, mechanical hemostats such as collagen-based, oxidized regenerated cellulose-based, gelatin-based, polysaccharide-based)].
- Among the broader product segments, the topical hemostats segment accounted for the largest share of the total tissue sealing and hemostasis agents market, whereas the adhesive and tissue sealing products segment expected to register the fastest CAGR during the forecast period.
- Topical hemostats have advantages over other wound closure devices in controlling bleeding in surgical procedures when ligatures or conventional procedures are ineffective or impractical, as well as being high efficacy and low product cost.
- Mechanical hemostats market sub-segment registered higher sales revenue, while active hemostats market forecast to grow at a higher rate over the next five years period. Mechanical hemostats are either cellulose, polysaccharide, collagen, or gelatin-base products.
- Oxidized regenerated cellulose-based (ORC-based) hemostats registered higher sales, in part driven by its physical properties and potent mode of action against a wide variety of pathogens.
- Mechanical hemostats market sub-segment registered higher sales revenue, while active hemostats market forecast to grow at a higher rate over the next five years period. Mechanical hemostats are either cellulose, polysaccharide, collagen, or gelatin-base products.
- However, the collagen-based topical hemostats providing faster coagulation, and its availability for a large number of surgical indications expected to be driving the market growth in the near future.
- Topical hemostats have advantages over other wound closure devices in controlling bleeding in surgical procedures when ligatures or conventional procedures are ineffective or impractical, as well as being high efficacy and low product cost.
The global market for tissue sealing and hemostasis agents is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.
- Geographically, the North America region accounted for the largest share of the total tissue sealing agents and hemostasis products market, followed by the Europe region, due to the rising number of surgical procedures in vascular, pulmonary, cardiovascular, and other areas.
- On the other hand, the emerging markets of Asia Pacific region expected to witness the fastest grow rate during the next few years, driven by growing patient base, presence of major companies and easy access to their tissue sealing and hemostasis products.
The global tissue sealing and hemostasis agents market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major competitors operating in global market for tissue sealing and hemostasis products included in the report are Advanced Medical Solutions Group plc, Baxter International, Inc., Cohera Medical, Inc., CryoLife, Inc., Becton, Dickinson and Company, Johnson & Johnson Services, Inc., Integra LifeSciences Corporation, and Pfizer, Inc.
- Product
- Adhesive and Tissue Sealing Agents
- Adhesion Barrier Products
- Natural Tissue Sealants
- Fibrin Sealants
- Other Natural Sealants (Albumin and Collagen-based)
- Synthetic Tissue Sealants
- Cynoacrylate-based Tissue Adhesives
- Other Synthetic Tissue Sealant (Polyethylene Glycol- based, etc.)
- Topical Hemostats
- Active Hemostats (Thrombin-based)
- Flowable Hemostats (Combination)
- Mechanical Hemostats
- Collagen-based
- Oxidized Regenerated Cellulose-based (ORC-based)
- Gelatin-based
- Polysaccharide-based
- Adhesive and Tissue Sealing Agents
- Geography
- North America (U.S., Canada)
- Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
- Asia Pacific (Japan, China, India, Rest of APAC)
- Latin America (Brazil, Mexico, Rest of LA)
- Rest of the World
- Company Profiles
- Advanced Medical Solutions Group plc
- Baxter International, Inc.
- Cohera Medical, Inc.
- CryoLife, Inc.
- Becton, Dickinson and Company
- Johnson & Johnson Services, Inc.
- Integra LifeSciences Corporation
- Pfizer, Inc.
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/tissue-sealing-agents-hemostasis-market/
Related publications:
